Grade III-A · Pulmonary specialty hospital
Established
1933
Beds
1,200+
Annual Volume
30,000+
Shanghai
Top-tier lung cancer volumes in China; Prof. Zhou Cai-Cun’s phase III immunotherapy trials have changed international guidelines.
Shanghai Pulmonary Hospital is China’s largest specialty hospital for pulmonary diseases, ranking first nationally in annual lung surgery volume and lung cancer caseload, and first in lung transplantation. Professor Zhou Caicun’s team has led multiple immunotherapy and targeted-therapy studies that changed international practice.
The hospital has complete systems for pulmonary-nodule differential diagnosis, early lung cancer screening and ablation therapy, with advanced bronchoscopic and percutaneous interventional platforms.
01Largest lung cancer caseload in China
Both surgical and medical lung-cancer volumes rank first nationally, with complete sub-lobar and precision segmentectomy techniques.
02Frontier of lung-cancer immunotherapy research
Series such as CAMEL and ORIENT led by Professor Zhou Caicun established domestic PD-1 inhibitors in first-line lung cancer, published in Lancet Respiratory Medicine and other journals.
03Precise pulmonary-nodule differentiation
An imaging–biomarker–AI combined nodule-assessment system reduces overtreatment and unnecessary follow-up.
Its volumes of minimally invasive lung cancer surgery and lung transplantation rank among the nation’s highest, covering the full chain from early nodule diagnosis to transplantation for end-stage lung disease.
The CameL study led by Prof. Zhou Caicun established a domestic PD-1 inhibitor plus chemotherapy as first-line treatment for advanced non-squamous lung cancer, published in The Lancet Respiratory Medicine.